Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma

Study start date: February 1, 1991

DISEASE CHARACTERISTICS: Diagnosis of refractory or relapsed ovarian epithelial cancer Must have failed prior regimen containing cisplatin or carboplatin Bidimensionally measurable or evaluable disease Serial CA-125 antigen titers or cytologically positive pleural effusion and/or ascites acceptable as evaluable disease Autologous bone marrow harvest of greater than 1.2 x 10 to the eighth nucleated cells/kg required before study entry No evidence of tumor at marrow harvest sites by bilateral bone marrow aspirates and biopsies, pelvic x-ray, and bone scan CNS involvement allowed PATIENT CHARACTERISTICS: Age: Under 65 Performance status: SWOG 0-2 Life expectancy: At least 8 weeks Hematopoietic: WBC greater than 3,500/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 10.0 g/dL Hepatic: Bilirubin less than 2.0 mg/dL SGOT and SGPT less than 2 times upper limit of normal Renal: Creatinine clearance greater than 60 mL/min No prior hemorrhagic cystitis Cardiovascular: LVEF greater than 45% by MUGA scan Other: No hearing loss in voice tones No active infection No psychological contraindication to study treatment Not pregnant Negative pregnancy test HIV negative General medical condition must allow general anesthesia PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior bone marrow transplantation More than 4 weeks since other prior biologic therapy and recovered Chemotherapy: See Disease Characteristics More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: Not specified Radiotherapy: More than 4 weeks since prior radiotherapy and recovered Surgery: Not specified